Analysts Maintain Optimism for Entrada Therapeutics Despite Stock Slump Shares of Entrada Therapeutics have dropped over 40% in the past year, hitting a 52-week low of $7.48. Despite the decline, analysts remain bullish, with price targets ranging from $20 to $30, citing the company’s strong cash position and promising pipeline targeting neuromuscular diseases.12